News|Articles|July 29, 2026

What FDA's Peptide Decision Means for the Industry

An FDA advisory panel voted to recommend six of seven unapproved peptides for compounding access, raising concerns about its newly appointed members.

In a two-day meeting that exposed deep fault lines, an FDA advisory committee voted to recommend that compounding pharmacies be allowed to manufacture six of seven unapproved peptides under review.